GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NuVasive Inc (NAS:NUVA) » Definitions » Tax Expense

NuVasive (NuVasive) Tax Expense : $13 Mil (TTM As of Jun. 2023)


View and export this data going back to 2004. Start your Free Trial

What is NuVasive Tax Expense?

NuVasive's tax expense for the months ended in Jun. 2023 was $5 Mil. Its tax expense for the trailing twelve months (TTM) ended in Jun. 2023 was $13 Mil.


NuVasive Tax Expense Historical Data

The historical data trend for NuVasive's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NuVasive Tax Expense Chart

NuVasive Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.76 15.28 -10.39 5.70 11.92

NuVasive Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 -0.84 7.92 1.19 5.12

NuVasive Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $13 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NuVasive  (NAS:NUVA) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


NuVasive Tax Expense Related Terms

Thank you for viewing the detailed overview of NuVasive's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


NuVasive (NuVasive) Business Description

Traded in Other Exchanges
N/A
Address
12101 Airport Way, Broomfield, CO, USA, 92121
NuVasive Inc is a medical technology company focused on developing, manufacturing, selling and providing procedural solutions for spine surgery, with a guiding purpose to transform surgery, advance care and change lives. The company has a portfolio of procedurally integrated spine surgery solutions, including surgical access instruments, spinal implants, fixation systems, biologics, and enabling technologies, as well as systems and services for intraoperative neuromonitoring. It also develop and sell magnetically adjustable implant systems for spine and specialized orthopedic procedures.
Executives
Michael Farrington officer: SVP, People and Culture 7475 LUSK BLVD., SAN DIEGO CA 92121
Marc W. Rosenbaum officer: Chief Accounting Officer 7475 LUSK BLVD., SAN DIEGO CA 92121
James Christopher Barry director, officer: Chief Executive Officer 7475 LUSK BLVD, SAN DIEGO CA 92121
Andrew C. Morton officer: SVP, CHRO 10910 DOMAIN DRIVE, SUITE 300, AUSTIN TX 78758
Amy Belt Raimundo director ONE KAISER PLAZA, 22ND FLOOR, OAKLAND CA 94612
Lucas Vitale officer: Chief Human Resources Officer 7475 LUSK BLVD, SAN DIEGO CA 92121
Massimo Calafiore officer: EVP, Global Business Units 7475 LUSK BLVD., SAN DIEGO CA 92121
Siddhartha Kadia director 7475 LUSK BOULEVARD, SAN DIEGO CA 92121
Vickie L Capps director 2985 SCOTT STREET, VISTA CA 92083
Brent J. Boucher officer: EVP, Global Commercial 14 PLAZA DRIVE, LATHAM NY 12110
Matthew Link officer: Exec. VP U.S. Sales 7475 LUSK BLVD, SAN DIEGO CA 92121
Matthew K Harbaugh officer: EVP and CFO 675 MCDONNELL BLVD., HAZELWOOD MO 63042
Dale A. Wolf officer: SVP, Global Operations 7475 LUSK BLVD., SAN DIEGO CA 92121
Gregory T Lucier director C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Paul Mcclintock officer: President, U.S. Commercial 7475 LUSK BLVD, SAN DIEGO CA 92121